KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Non-cash Items (2016 - 2024)

Historic Non-cash Items for Sarepta Therapeutics (SRPT) over the last 14 years, with Q4 2024 value amounting to $425.0 million.

  • Sarepta Therapeutics' Non-cash Items rose 704116.86% to $425.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $425.0 million, marking a year-over-year increase of 704116.86%. This contributed to the annual value of $425.0 million for FY2024, which is 704116.86% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Non-cash Items of $425.0 million as of Q4 2024, which was up 704116.86% from $6.0 million recorded in Q4 2023.
  • Over the past 5 years, Sarepta Therapeutics' Non-cash Items peaked at $425.0 million during Q4 2024, and registered a low of $2.0 million during Q4 2020.
  • Its 5-year average for Non-cash Items is $137.2 million, with a median of $6.0 million in 2023.
  • Per our database at Business Quant, Sarepta Therapeutics' Non-cash Items skyrocketed by 1219898.01% in 2021 and then crashed by 9811.15% in 2022.
  • Sarepta Therapeutics' Non-cash Items (Quarter) stood at $2.0 million in 2020, then surged by 12198.98% to $248.5 million in 2021, then tumbled by 98.11% to $4.7 million in 2022, then rose by 26.84% to $6.0 million in 2023, then skyrocketed by 7041.17% to $425.0 million in 2024.
  • Its last three reported values are $425.0 million in Q4 2024, $6.0 million for Q4 2023, and $4.7 million during Q4 2022.